Latest Credit Agreements News

A wild week for small-cap tech, led by a price-query rocket in DTI and a heavy sell-off in Qoria despite strong recurring revenue growth. Cash receipts, contract wins and capital raises did most of the talking, while a few gap moves showed how fast early gains can vanish.

Light & Wonder, Inc. has amended its credit agreement to introduce a new $2.13 billion tranche of term loans due in 2029, replacing prior debt and reducing borrowing costs. The move reflects a strategic refinancing amid its Nasdaq delisting process.

AVITA Medical reported an 18% revenue increase in Q3 2025 driven by new product launches and deeper market penetration, while continuing to face net losses and credit covenant challenges. The company also announced a CEO departure and interim leadership appointment.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Light & Wonder, Inc. reported a 3% revenue increase for Q3 2025, driven by its Gaming and iGaming segments, alongside completing the Grover acquisition and refinancing debt with $1 billion in senior notes.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Burgundy Diamond Mines reported a robust A$80.4 million net cash inflow from operations in Q3 2025, offset by significant capital expenditure on its Point Lake project and ongoing loan repayments.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

James Hardie Industries has successfully syndicated $3.5 billion in new credit facilities, providing robust financial backing for its planned merger with The AZEK Company Inc. This move significantly reduces prior bridge loan commitments and enhances the company’s financial flexibility.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.